Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07588139 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary completion date changed from estimate of Sep 3, 2026 to Sep 8, 2026 · Study completion date changed from estimate of Sep 19, 2026 to Oct 5, 2026 · Eligibility criteria expanded, about 42 words · 2 more Show 5 more changesShow less
    • Primary completion date changed from estimate of Sep 3, 2026 to Sep 8, 2026
    • Study completion date changed from estimate of Sep 19, 2026 to Oct 5, 2026
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: details revised at 8 of 21 entries
    • Site details revised
  2. Study Status, Referencesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Trial Details
NCT Number NCT07588139
Lead Sponsor Incyte Corporation
Conditions Healthy Participants
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov